Nearly one-third of patients who have early-stage breast cancer will develop advanced disease. This is the most serious form of the disease and it occurs when the cancer has spread to other parts of the body, such as the lymph nodes, brain, bones or liver. The survival rate of women living with advanced breast cancer are lower than those for women with earlier stage disease.
The FDA recently approved a new class of drugs called cyclin-dependent kinase inhibitors. These drugs along with hormonal therapy can help slow down the progression of estrogen-receptor positive advanced or metastatic breast Cancer.
Monday On the WEOL Morning Show, Bruce and Craig spoke with Dr. Denise Yardley, MD about the new treatment and how those interested can get involced in clinical trials. Listen to the interview here.